Buy Dasanix (Dasatinib) 20/50/100 mg online, Buy Sprycel online
Dasanix (Sprycel) Dasatinib 20/50/100 mg by Beacon Pharmaceuticals is used to treat Chronic Myeloid Leukemia-CML, Acute Lymphoblastic Leukemia-ALL).
Dasanix is the alternative & generic version of Sprycel by Bristol Myers Squibb. Dasanix is manufactured by Beacon Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.
Therapeutic Class
Targeted Cancer Therapy
Pharmacology
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.
In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL.
Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
Dosage & Administration
The recommended starting dosage of Dasatinib for:
-
Chronic phase CML is 100 mg administered orally once daily.
-
Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL is 140 mg administered orally once daily.